pharma & biotech

Advanced genomic tools have provided biotech companies new approaches to help our furry friends—but experts say several limitations remain.

This year’s award recognizes Carolyn Bertozzi, Morten Meldal, and K. Barry Sharpless for developing click chemistry and bioorthogonal chemistry.

Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?

The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.

Canada has ordered 76 million doses of Covifenz, the main ingredient of which was manufactured in the leaves of a tobacco relative.

The biotech industry is chipping away at the obstacles standing between the lab and the dinner plate.

RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.

The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.

RNA editing platforms leverage the natural activity of ADAR enzymes to make key changes to messenger RNAs before they are translated into proteins.

The cardiologist was briefly the FDA Commissioner in the Obama Administration, and now has a second chance to act on plans he tried to implement during his first tenure.

Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.

Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.

With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.

In the largest effort to date to standardize performance metrics of the cancer diagnostic across products, researchers say the products can likely detect advanced tumors reliably, but early-stage malignancies would remain a challenge.

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

The former GlaxoSmithKline executive had led the US government’s Operation Warp Speed COVID-19 vaccine program during the Trump administration.

The microbiome-testing company made misleading claims about its prospects and about its business strategy, which allegedly relied on fooling doctors into ordering unnecessary tests, according to the US government.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Clinical trials were halted after the treatment’s vector that ferries in the healthy genetic sequence was identified in the genome of a patient’s cancer cells.